

NEWS

International Kidney Cancer Coalition (IKCC) Announces New Medical Advisory Board

The International Kidney Cancer Coalition (IKCC) completed its 8th Expanding Circles 2018 Annual Conference from April 12th - 14th, 2018 in Mexico City, Mexico and announces new Medical Advisory Board.



Mexico City, Mexico April 13, 2018

The International Kidney Cancer Coalition (IKCC) held its 8th Expanding Circles in Kidney Cancer Conference – the International Conference for Organisations Representing Patients with Kidney Cancer -- from April 12th-14th, 2018 in Mexico City, Mexico. During the Annual General Meeting, Dr. Rachel Giles, Chair of IKCC, announced the organisation's inaugural Medical Advisory Board.

Dr. Michael A.S. Jewett, IKCC Board Member (CA) will Chair the new Medical Advisory Board and Dr. Eric Jonasch, IKCC Board Member (USA) will join as Vice Chair. Medical Advisory Board members welcomed were:

- Dr. Axel Bex, Department of Urology, Netherlands Cancer Institute (NL)
- Dr Daniel Heng, Clinical Associate Professor, Tom Baker Cancer Centre, Calgary (CA)
- Dr. James Larkin, Consultant Medical Oncologist at the Royal Marsden Hospital in London (UK).

Thank you to these internationally renowned experts in kidney cancer for their commitment to global collaboration and patient engagement.

Board Chair Dr. Rachel Giles commented that “we are delighted to strengthen the professional impact of the IKCC with the formation of an innovative Medical Advisory Board that will work alongside patient organisations worldwide to reduce the global burden of kidney cancer.”

The 8th International Kidney Cancer Coalition Conference for organisations representing kidney cancer patients was attended by over 50 kidney cancer advocates from 25 countries from six continents.

Throughout the three-day meeting patient organisation leaders learned about latest developments in kidney cancer care, discussed active patient involvement and shared experiences with national healthcare policies. This meeting was held alongside a Clinical Experts meeting hosted by the Latin American Renal Cancer Group (LARCG) the Mexican Society of Urology (SMU) and the Mexican Association of Urological Oncology (MAUO).

This meeting in Mexico City was particularly exceptional in raising awareness of kidney cancer in Mexico and Latin America through a breakfast meeting hosted by Asociación ALE and by combining patient organisations and clinical experts together in joint sessions where they could share perspectives on matters important to patients worldwide” summarized Dr. Rachel Giles, Board Chair and patient advocate from Dutch VHL Organisation and founding member. “I am very glad to welcome Dr. Bex, Dr. Heng and Dr. Larkin to this unique multi-disciplinary IKCC collaboration and to strengthen our global coalition of organisations working together to reduce the global burden of kidney cancer.”

News Item 2:

New Board Directors elected at Annual General Meeting, Mexico City April 13



During the Annual General Meeting of the IKCC, two experienced kidney cancer patient advocates were elected to the IKCC Board of Directors: Bryan Lewis of Kidney Cancer Action Network (KCAN) in the United States, and Berit Eberhardt of Uronauten e.V., an organisation serving patients with rare genitourinary cancers in Germany.



Board Chair Dr. Rachel Giles commented that, “with this board election, we give our heartfelt thanks to Joyce Graff, who has served as a board member since 2012. Joyce will take on the role of IKCC Board Senator (the newly approved designation for Emerita) and will remain a valued representative of the IKCC Affiliate Organisation Powerful Patient. Joyce will also serve on the IKCC Nominations Committee going forward.”

About KIDNEY CANCER

Kidney cancer is diagnosed in over 300,000 people worldwide every year. It is the 12th most common cancer in the world, with approximately the same incidence as pancreatic cancer. Fewer than 1 in 20 people diagnosed with cancer have kidney cancer, meaning that it is quite a rare disease. When detected early, kidney cancer patients have very favourable survival outcomes. However, up to one third of kidney cancer patients are diagnosed at the advanced stage. There is no known cure for advanced kidney cancer although treatments can extend survival for many patients. Further research and new treatments are needed.

About the International Kidney Cancer Coalition (IKCC)

The International Kidney Cancer Coalition (IKCC), a registered foundation based in The Netherlands. The IKCC is an independent, democratic and patient-centred network comprising 33 Affiliate Organisations from around the world. The organisation was born from a very strong desire among various national patient groups to network, cooperate and share experiences.

For more information please view the IKCC website www.ikcc.org

Search for us on Facebook as: **IKCC**

Follow us on Twitter: **@IKCCorg** and **@IKCCtrials**

Media Contacts

Dr. Rachel Giles – English/Dutch

(Belangenvereniging Von Hippel-Lindau (VHL), The Netherlands)

Staff, Internal Medicine

Dept. Nephrology and Hypertension

University Medical Center Utrecht

The Netherlands

Chair of the IKCC-Board

r.giles@umcutrecht.nl

Deborah Maskens – English

(Kidney Cancer Canada)

Vice Chair of the IKCC Board debmaskens@kidneycancer canada.ca

Central Contact:

IKCC UK (Mobile) +44 (0) 7973 777 202

contact@ikcc.org

www.ikcc.org

www.worldkidneycancerday.org